US Adult Obesity Rate Falls to 36.8% as GLP-1 Use Hits 11% — First Population-Level Reversal on Record

US Adult Obesity Rate Falls to 36.8% as GLP-1 Use Hits 11% — First Population-Level Reversal on Record

A datapoint with no precedent in modern US public health landed this week in a Motley Fool analysis (Oct. 16, 2026): "The adult obesity rate in the U.S. has fallen from 39.9% in 2022 to 36.8% in 2026¹." The decline coincides with the steepest adoption curve in the class's history — per Gallup: "The percentage of U.S. adults taking these weight loss drugs has risen to 11% this year, from 3% just two years ago. And 15% of U.S. adults report having used the medicine at some point," with injectable use for weight loss nearly quadrupling since 2024.

Forward adoption forecasts cited in the same piece:

• J.P. Morgan Global Research: ~25 million Americans on GLP-1 treatment by 2030, up from ~10 million last year (including T2D patients).
• Morgan Stanley: the GLP-1 market more than doubles from 2025 to 2035, to $190 billion.

The longevity tailwind got laboratory support the same week: an NIH-funded University of California study in healthy older mice found semaglutide extended lifespan by tempering aging itself, beyond calorie restriction. Per the NIH release: "Compared with a control group, mice treated with the drug showed improved muscle and cognitive function. Gene expression analysis showed that several hallmarks of natural aging, such as increased inflammation and reduced regenerative capacity, were reduced in treated animals." The Fool's framing captures the investment logic: "the research remains a long way from establishing the same anti-aging results in humans. But if people believe it might, that will only encourage adoption of the drugs." This dovetails with the human epigenetic-clock data in GLP-1s Emerge as Longevity Candidates: Novo and Lilly Report 2–3 Year Reductions in Biological Age — the open question there (a formal geroprotection R&D program) remains unanswered, but the narrative fuel keeps accumulating.

Investor take: A falling national obesity rate is the single clearest evidence the drugs work at population scale — it validates the TAM expansion thesis (more indications, more payers, more geographies) and the consumer ripple effects tracked in GLP-1 Drugs Reshaping Restaurant Industry: 12% of US Adults on Therapy, 8% Spending Cut at Fast Food and Wells Fargo: GLP-1 Adoption Is a Multi-Year Apparel Tailwind — Footwear Left Behind. It also sharpens the policy tension: demand this elastic against employer coverage exits (Employer GLP-1 Coverage Pullback Quantified: 10%+ of Covering Employers Eye 2027 Exit; Massachusetts Commercial Use Fell 50%) means access, not appetite, is the binding constraint on the $190B forecast.